Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare-associated infections - Sorbonne Université Access content directly
Journal Articles MedChemComm Year : 2016

Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare-associated infections

Abstract

The antiseptic and disinfectant potential of a formulation containing the tamoxifen analogue 1,1-bis[4-(3-dimethylaminopropoxy)phenyl]-2-ferrocenyl-but-1-ene citrate was assessed according to European standards and pharmacopeia in comparison with a commercial antiseptic product containing hexamidine diisethionate, chlorhexidine digluconate and chlorocresol as active ingredients. The formulation met the phase 1 requirement of reducing by 5 cycles the counts of microorganisms frequently involved in healthcare-associated infections, namely Escherichia coli ATCC 10536, Pseudomonas aeruginosa ATCC 15442, Staphylococcus aureus ATCC 6538, Enterococcus hirae ATCC 10541 and Candida albicans ATCC 10231. It also killed a clinical isolate of Acinetobacter baumannii which is highly resistant to antibiotics and antiseptics. In phase 2/step 2 tests, it reduced the counts of E. coli ATCC 10536 by 4 log cycles within 60 seconds on hands (standard EN 1499). The novel formula is a potent biocide, and this demonstration could lead to the development of a new commercial antiseptic.
Fichier principal
Vignette du fichier
Arbi_2016_Efficacy_of_a_novel.pdf (628.71 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01289145 , version 1 (16-03-2016)

Identifiers

Cite

Mehdi El Arbi, Karim Jalléli, Fatma Trigui, Pascal Pigeon, Meral Görmen, et al.. Efficacy of a novel ferrocenyl diaryl butene citrate compound as a biocide for preventing healthcare-associated infections. MedChemComm, 2016, 7 (5), pp.948-954. ⟨10.1039/C5MD00568J⟩. ⟨hal-01289145⟩
258 View
221 Download

Altmetric

Share

Gmail Facebook X LinkedIn More